The Paris Court of Appeal fines a pharmaceutical company € 17 M for unfair competition when launching a new drug (Ipsen / Mylan)

1. Summary Mylan, the generic pharmaceutical company (formerly Merck Génériques), was ordered by the Paris Court of Appeal to pay €17 million in damages to Ipsen for unfair competitive practices and economic parasitism by marketing Vitalogink to pharmacists as an "equivalent" to Tanakan and thereby voluntarily creating a confusion aimed at assimilating an original drug to a generic one. 2. Facts and procedure Beaufour Ipsen Pharma SAS is a subsidiary of the French independent drugmaker Ipsen Pharma. The company manufactures and markets medicinal and botanical medicines in France. One of its leading products, Tanakan, is indicated in particular for the treatment of age-related cognitive disorders and neurosensorial deficit. Based on a German patent (which expired in 2010), Tanakan

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Christophe Collard, The Paris Court of Appeal fines a pharmaceutical company € 17 M for unfair competition when launching a new drug (Ipsen / Mylan), 28 avril 2011, e-Competitions Judicial review, Art. N° 38945

Visites 1138

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues